Evogene PE Ratio 2012-2021 | EVGN

Current and historical p/e ratio for Evogene (EVGN) from 2012 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Evogene PE ratio as of October 26, 2021 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Evogene PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2021-10-27 2.55 0.00
2021-06-30 3.42 $-0.74 0.00
2021-03-31 5.04 $-0.75 0.00
2020-12-31 4.70 $-0.82 0.00
2020-09-30 3.96 $-0.81 0.00
2020-06-30 1.00 $-0.80 0.00
2020-03-31 1.18 $-0.80 0.00
2019-12-31 1.52 $-0.71 0.00
2019-09-30 1.58 $-0.70 0.00
2019-06-30 1.61 $-0.73 0.00
2019-03-31 1.83 $-0.76 0.00
2018-12-31 1.98 $-0.82 0.00
2018-09-30 3.11 $-0.83 0.00
2018-06-30 2.86 $-0.84 0.00
2018-03-31 3.18 $-0.83 0.00
2017-12-31 3.07 $-0.81 0.00
2017-09-30 4.44 $-0.83 0.00
2017-06-30 5.06 $-0.83 0.00
2017-03-31 5.35 $-0.83 0.00
2016-12-31 5.10 $-0.77 0.00
2016-09-30 6.38 $-0.73 0.00
2016-06-30 6.24 $-0.66 0.00
2016-03-31 6.51 $-0.68 0.00
2015-12-31 8.05 $-0.68 0.00
2015-09-30 8.25 $-0.65 0.00
2015-06-30 8.84 $-0.69 0.00
2015-03-31 8.82 $-0.62 0.00
2014-12-31 9.21 $-0.58 0.00
2014-09-30 13.16 $-0.59 0.00
2014-06-30 16.38 $-0.48 0.00
2014-03-31 19.05 $-0.40 0.00
2013-12-31 19.65 $-0.32 0.00
2013-09-30 15.20 $-0.14 0.00
2013-06-30 12.80 $-0.11 0.00
2013-03-31 10.10 $-0.09 0.00
2012-12-31 9.40 $-0.07 0.00
2012-09-30 7.50 $0.04 187.50
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.067B $0.001B
Evogene is a leading computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. Incorporating a deep understanding of biology and leveraging Big Data and Artificial Intelligence, Evogene established its unique technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. Evogene holds a number of subsidiaries utilizing the CPB platform to develop human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86